Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Adv
A phase 1/2 trial of Gemcitabine + nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Onconic Therapeutics Inc., now recruiting.
Overview
Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer is a phase 1/2 interventional study registered as NCT05257993 by Onconic Therapeutics Inc., with 71 participants planned, started 2022-03-30 and due to reach its primary completion in 2030-04. Interventions recorded: JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel. Conditions listed: Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSaltikva for Metastatic Pancreatic Cancer
Shares Gemcitabine + nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialPANOVA-3
Shares Gemcitabine + nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialNAPOLI 3
Shares Gemcitabine + nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- Key paperMPACT (Von Hoff 2013): nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer
Shares Gemcitabine + nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- CancerAmpullary cancer (ampulla of Vater)
Shares Gemcitabine + nab-paclitaxel, Pancreatic ductal adenocarcinoma.